Race Oncology (ASX:RAC) filed a new composition of matter patent application as well as two additional patent applications covering the optimal manufacturing, formulation, and uses of (E,E)-bisantrene isomer after scientific discoveries into the nature of bisantrene, according to a Tuesday Australian bourse filing.

The firm discovered that each isomer of bisantrene has differing biological properties and anticancer activity. The bisantrene isomers are generated during chemical synthesis or by exposure to visible light and heat. Only the (E,E)-bisantrene isomer has significant anticancer activity.

The patent applications were filed on Sept. 12. They requested accelerated examination of the new applications to aid pharmaceutical partnering discussions.

Its shares jumped 24% in recent trading on Tuesday, reaching the highest point in over two years.